Rapport Therapeutics (RAPP) director Wendy Young awarded 15,200 stock options at $35.21

Rhea-AI Filing Summary

Rapport Therapeutics director Wendy B. Young received a grant of stock options covering 15,200 shares of Common Stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, she holds 15,200 options directly.

The 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next Annual Meeting of Stockholders, as long as she continues to serve with the company through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Young Wendy B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 15,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,200 options Exercise price: $35.21 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 15,200 options Stock Option (Right to Buy) grant to director

Exercise price $35.21 per share Stock option exercise price

Expiration date June 10, 2036 Option expiration

Post-transaction derivative holdings 15,200 options Total options directly owned after grant

Vesting date trigger Earlier of June 10, 2027 or next annual meeting Vesting condition for option grant

Key Terms

Stock Option (Right to Buy), underlying security, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

underlying security financial

"underlying_security_title: Common Stock"

exercise price financial

"conversion_or_exercise_price: 35.2100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Wendy B.

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.21	06/10/2026		A		15,200		(1)	06/10/2036	Common Stock	15,200	$0	15,200	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Rapport Therapeutics (RAPP) disclose in this Form 4 for Wendy B. Young?

Rapport Therapeutics reported that director Wendy B. Young received a stock option grant for 15,200 shares. These options give her the right to buy Common Stock at a fixed price, reflecting routine equity-based compensation for board service.

How many options did Wendy B. Young receive from Rapport Therapeutics (RAPP)?

She received stock options covering 15,200 shares of Common Stock. This entire amount is reflected as directly owned options after the transaction, indicating the filing only reports this new grant, not additional existing option holdings.

What is the exercise price and expiration date of Wendy Young’s RAPP options?

The options have an exercise price of $35.21 per share and expire on June 10, 2036. This means she can choose to buy Rapport Therapeutics stock at $35.21 any time before that expiration date, once the options have vested.

When do Wendy B. Young’s Rapport Therapeutics options vest?

The options vest on the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders. Vesting is conditioned on her continued service with Rapport Therapeutics through that date, aligning her incentives with long-term company performance.

Is Wendy B. Young buying or selling RAPP shares in this Form 4?

This Form 4 does not show a market purchase or sale of RAPP shares. It reports an acquisition of stock options as compensation, classified as a grant or award, rather than an open-market buy or sell transaction.

What is Wendy B. Young’s position at Rapport Therapeutics (RAPP)?

She is identified as a director of Rapport Therapeutics. The reported stock option grant is typical for director compensation, providing equity exposure that links her potential upside to the company’s future stock performance once options vest and are exercisable.